Health Facts

DIABETES

MANAGEMENT:

MEDEM ( Monitoring, Education, Diet, Exercise, Medication)

  1. Monitoring (HbA1c of 7% or lower, self monitoring of blood glucose, urine glucose & ketone)
  2. Education (role of educator?)
  3. Dietary modification (caloric restriction for obese patients, role of educator?)
  4. Exercise (benefits in DM patients)

MEDICATIONS

      - Baby Aspirin is proven of benefit in secondary prevention of MI & stroke in DM patients

 

HYPERTENSION

MANAGEMENT

 

HIGH CHOLESTEROL (HYPERLIPIDEMIA)

 

MANAGEMENT

MEDICATIONS

 

GERD (gastroesophageal reflux disease)

MANAGEMENT:

MEDICATIONS:

 

HEPATITIS

            HBV is a global epidemic
            Despite there being a vaccine, HBV still kills up to 1 million people
            worldwide
            About 370 million individuals in the world live with chronic HBV
            HBV is 100X more infectious than HIV
            As many as 1 in 10 foreign-born Asians are chronically infected with HBV
            As many as 2 out of 3 chronically infected persons are unaware of their
            infection
            Without appropriate monitoring or treatment, 1 in 4 will die from liver
            cancer or liver failure.
            Every 30-45 seconds, one person dies from this vaccine-preventable
            disease

            Liver cancer is a silent killer because patients typically show no
            symptoms until the end stages of the disease.
            Asians who are chronically infected by HBV at birth or during childhood
            may develop liver cancer as early as their teens
            If diagnosed late, liver cancer is one of the most difficult cancers to treat.
            Early detection and screening can lead to successful surgical removal
            and long-term survival.

            Many chronically infected persons show no outward signs of HBV
            infection, therefore screening for HBV is necessary to:

            Hepatitis B surface antigen (HBsAg):  If a patient remains HBsAg-
            positive for more than 6 months, they have chronic HBV infection.
            Hepatitis B surface antibody (anti-HBs):  The anti-HBs test will tell if your
            patient is protected against HBV.  Anti-HBs can be produced in response
            to vaccination or recovery from an acute hepatitis B infection.

The following oral antivirals inhibit replication of HBV:
Lamivudine (Epivir-HBV, approved 1998)
Adefovir (Hepsera, approved 2002)
Entecavir (Baraclude, approved 2005)
Telbivudine (Tyzeka, approved 2006)
Common side-effects include:  The main adverse outcome is drug-resistent mutant viruses.  Side effects are uncommon and usually mild (weakness, headache, fatigue, diarrhea, and stomach pain).  Adefovir has potential renal toxicity, though it is uncommon.

 

CATARACT

 

 

GLAUCOMA

 

AGE-RELATED MACULAR DEGENERATION

 

DIABETIC EYE DISEASE (Diabetic Retinopathy)

 

OTHER COMMON EYE CONDITIONS